Logo image of ALBLU.PA

BLUELINEA (ALBLU.PA) Stock Fundamental Analysis

EPA:ALBLU - Euronext Paris - Matif - FR0011041011 - Common Stock - Currency: EUR

0.54  -0.01 (-0.92%)

Fundamental Rating

1

ALBLU gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 57 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of ALBLU have multiple concerns. ALBLU is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALBLU had negative earnings in the past year.
ALBLU had a positive operating cash flow in the past year.
In the past 5 years ALBLU always reported negative net income.
ALBLU had a negative operating cash flow in each of the past 5 years.
ALBLU.PA Yearly Net Income VS EBIT VS OCF VS FCFALBLU.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1M -2M -3M -4M

1.2 Ratios

Looking at the Return On Assets, with a value of -16.32%, ALBLU is doing worse than 68.42% of the companies in the same industry.
ALBLU has a Return On Equity of -115.32%. This is amonst the worse of the industry: ALBLU underperforms 82.46% of its industry peers.
Industry RankSector Rank
ROA -16.32%
ROE -115.32%
ROIC N/A
ROA(3y)-22.53%
ROA(5y)-28.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALBLU.PA Yearly ROA, ROE, ROICALBLU.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 -200 -300

1.3 Margins

The Gross Margin of ALBLU (103.22%) is better than 98.25% of its industry peers.
In the last couple of years the Gross Margin of ALBLU has remained more or less at the same level.
ALBLU does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 103.22%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.66%
GM growth 5Y1.04%
ALBLU.PA Yearly Profit, Operating, Gross MarginsALBLU.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50

More info and screens

0

2. Health

2.1 Basic Checks

ALBLU does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALBLU remains at a similar level compared to 1 year ago.
The number of shares outstanding for ALBLU has been increased compared to 5 years ago.
ALBLU has a worse debt/assets ratio than last year.
ALBLU.PA Yearly Shares OutstandingALBLU.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
ALBLU.PA Yearly Total Debt VS Total AssetsALBLU.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

ALBLU has an Altman-Z score of -3.00. This is a bad value and indicates that ALBLU is not financially healthy and even has some risk of bankruptcy.
ALBLU's Altman-Z score of -3.00 is on the low side compared to the rest of the industry. ALBLU is outperformed by 82.46% of its industry peers.
A Debt/Equity ratio of 2.31 is on the high side and indicates that ALBLU has dependencies on debt financing.
ALBLU has a worse Debt to Equity ratio (2.31) than 82.46% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.31
Debt/FCF N/A
Altman-Z -3
ROIC/WACCN/A
WACC6.81%
ALBLU.PA Yearly LT Debt VS Equity VS FCFALBLU.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2M -2M 4M -4M 6M 8M

2.3 Liquidity

ALBLU has a Current Ratio of 0.49. This is a bad value and indicates that ALBLU is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.49, ALBLU is not doing good in the industry: 87.72% of the companies in the same industry are doing better.
ALBLU has a Quick Ratio of 0.49. This is a bad value and indicates that ALBLU is not financially healthy enough and could expect problems in meeting its short term obligations.
ALBLU has a worse Quick ratio (0.44) than 84.21% of its industry peers.
Industry RankSector Rank
Current Ratio 0.49
Quick Ratio 0.44
ALBLU.PA Yearly Current Assets VS Current LiabilitesALBLU.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M

More info and screens

2

3. Growth

3.1 Past

ALBLU shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.35%, which is quite good.
Looking at the last year, ALBLU shows a decrease in Revenue. The Revenue has decreased by -5.60% in the last year.
ALBLU shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.78% yearly.
EPS 1Y (TTM)19.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.56%
Revenue 1Y (TTM)-5.6%
Revenue growth 3Y12.92%
Revenue growth 5Y9.78%
Sales Q2Q%-6.48%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALBLU.PA Yearly Revenue VS EstimatesALBLU.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
ALBLU.PA Yearly EPS VS EstimatesALBLU.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 -0.1 -0.2 -0.3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALBLU. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALBLU.PA Price Earnings VS Forward Price EarningsALBLU.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

The rest of the industry has a similar Enterprise Value to EBITDA ratio as ALBLU.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 35.56
ALBLU.PA Per share dataALBLU.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALBLU!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BLUELINEA

EPA:ALBLU (7/11/2025, 7:00:00 PM)

0.54

-0.01 (-0.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners83.76%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap9.95M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.7
P/FCF N/A
P/OCF 21.64
P/B 4.54
P/tB N/A
EV/EBITDA 35.56
EPS(TTM)-0.14
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)0.02
OCFY4.62%
SpS0.77
BVpS0.12
TBVpS-0.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.32%
ROE -115.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 103.22%
FCFM N/A
ROA(3y)-22.53%
ROA(5y)-28.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.66%
GM growth 5Y1.04%
F-Score5
Asset Turnover0.92
Health
Industry RankSector Rank
Debt/Equity 2.31
Debt/FCF N/A
Debt/EBITDA 13.16
Cap/Depr 144.22%
Cap/Sales 27.72%
Interest Coverage N/A
Cash Conversion 119.5%
Profit Quality N/A
Current Ratio 0.49
Quick Ratio 0.44
Altman-Z -3
F-Score5
WACC6.81%
ROIC/WACCN/A
Cap/Depr(3y)140.81%
Cap/Depr(5y)112.84%
Cap/Sales(3y)19.23%
Cap/Sales(5y)15.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.56%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-5.6%
Revenue growth 3Y12.92%
Revenue growth 5Y9.78%
Sales Q2Q%-6.48%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y1.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-232.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y921.33%
OCF growth 3YN/A
OCF growth 5YN/A